Φορτώνει......
A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia
BACKGROUND: Treatment of sickle cell anemia is a challenging task and despite the well understood genetic and biochemical pathway of sickle hemoglobin, current therapy continues to be limited to the symptomatic treatment of pain, supplemental oxygen, antibiotics, red blood cell transfusions and hydr...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Rev Bras Hematol Hemoter |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Sociedade Brasileira de Hematologia e Hemoterapia
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5339363/ https://ncbi.nlm.nih.gov/pubmed/28270341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bjhh.2016.08.004 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|